王惜彤,张玉英

代谢相关脂肪性肝病（MAFLD）曾用名为非酒精性脂肪性肝病（NAFLD）。目前，随着人们不健康的生活习惯的增加，MAFLD已成为全人类最常见的慢性肝病，对人类健康造成了严重威胁。心血管疾病（CVD）是常见的慢性非传染性疾病，也是全球范围内主要死亡原因之一。MAFLD患者的死亡原因主要是心血管疾病，而不是肝脏原因。本文就目前MAFLD与CVD相关性的临床证据和潜在的病理生理机制以及治疗方法进行综述，以期为临床防治及未来的研究提供方向。

代谢相关脂肪性肝病；心血管疾病；发病机制；治疗

[1] Riazi K,Azhari H,Charette J H,et al.The prevalence and incidence of NAFLD worldwide:a systematic review and meta-analysis[J].The lancet gastroenterology&hepatology,2022,7(9):851-861. [2] MantovaniA,Scorletti E,MoscaA,et al.Complications,morbidity and mortality of nonalcoholic fatty liver disease[J].Metabolism,2020,111:154170. [3] Eslam M,Sanyal A J,George J,et al.MAFLD:a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J].Gastroenterology,2020,158(7):1999-2014.e1. [4] Targher G,Corey K E,Byrne C D.NAFLD,and cardiovascular and cardiac diseases:Factors influencing risk,prediction andtreatment[J].Diabetes Metab,2021,47(2):101215. [5] Dongiovanni P,Paolini E,Corsini A,et al.Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases:from epidemiology to drug approaches[J].Eur J Clin Invest,2021,51(7):e13519. [6] Mantovani A,Csermely A,Tilg H,et al.Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events:a meta-analysis of about 13 million individuals[J].Gut,2023,72(7):1433-1436. [7] Niriella M A,Ediriweera D S,Kasturiratne A,et al.Outcomes of NAFLD and MAFLD:results from a community-based,prospective cohort study[J].PloS one,2021,16(2):e0245762. [8] Lee H J,Lee C H,Kim S,et al.Association between vascular inflammation and non-alcoholic fatty liver disease:analysis by 18F-fluorodeoxyglucose positron emission tomography[J].Metabolism,2017,67:72-79. [9] Liu S,Wang J,Wu S,et al.The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis:A prospective analysis[J].Metabolism,2021,120:154779. [10] Peng D,Yu Z,Wang M,et al.Association of metabolic dysfunction-associated fatty liver disease with left ventricular diastolic function and cardiac morphology[J].Frontiers in Endocrinology,2022,13:935390. [11] Nguyen V H,Le M H,Cheung R C,et al.Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD[J].Clin Gastroenterol H,2021,19(10):2172-2181.e6. [12] Powell-Wiley T M,Poirier P,Burke L E,et al.Obesity and cardiovascular disease:a scientific statement from the American Heart Association[J].Circulation,2021,143(21):e984-e1010. [13] von Jeinsen B,Vasan R S,McManus D D,et al.Joint influences of obesity,diabetes,and hypertension on indices of ventricular remodeling:findings from the community-based Framingham Heart Study[J].PLoS One,2020,15(12):e0243199. [14] Deprince A,Haas J T,Staels B.Dysregulated lipid metabolism links NAFLD to cardiovascular disease[J].Mol Metab,2020,42:101092. [15] Flores ‐ Guerrero J L,Westenbrink B D,Connelly M A,et al.Association of beta ‐ hydroxybutyrate with development of heart failure:sex differences in a Dutch population cohort[J].Eur J Clin Invest,2021,51(5):e13468. [16] Li F,Ye J,Shao C,et al.Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients:A systematic review and Meta-analysis[J].Lipids in Health and Disease,2021,20:1-12. [17] Eslam M,Sarin S K,Wong V W S,et al.The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J].Hepatol Int,2020,14:889-919. [18] Tang W,Xu Q,Hong T,et al.Comparative efficacy of anti‐diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus:a systematic review and meta‐analysis of randomized and non‐randomized studies[J].Diabetes/metabolism research and reviews,2016,32(2):200-216.

点击下载PDF